Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological diagnostics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jane Chao, Ph.D., CEO and Co-founder, will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. PST.
The presentation will be accessible through a live and archived webcast in the Investor Relations section of Ceribell's website. The company focuses on revolutionizing the diagnosis and management of serious neurological conditions through innovative medical technology solutions.
Ceribell (Nasdaq: CBLL), un'azienda tecnologica medica specializzata nella diagnostica neurologica, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Jane Chao, Ph.D., CEO e co-fondatrice, presenterà un intervento lunedì 13 gennaio 2025, alle 7:30 a.m. PST.
La presentazione sarà accessibile tramite un webcast in diretta e archiviato nella sezione Relazioni con gli Investitori del sito web di Ceribell. L'azienda si concentra sulla rivoluzione della diagnosi e della gestione di gravi condizioni neurologiche attraverso soluzioni innovative di tecnologia medica.
Ceribell (Nasdaq: CBLL), una empresa de tecnología médica especializada en diagnósticos neurológicos, ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. Jane Chao, Ph.D., CEO y cofundadora, presentará una exposición el lunes 13 de enero de 2025, a las 7:30 a.m. PST.
La presentación estará disponible a través de un webcast en vivo y archivado en la sección de Relaciones con Inversores del sitio web de Ceribell. La empresa se enfoca en revolucionar el diagnóstico y la gestión de condiciones neurológicas graves mediante soluciones innovadoras de tecnología médica.
세리벨 (Nasdaq: CBLL), 신경학적 진단을 전문으로 하는 의료 기술 회사가 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. Jane Chao, Ph.D. CEO이자 공동 창립자는 2025년 1월 13일 월요일 오전 7시 30분 PST에 발표를 할 예정입니다.
발표는 세리벨 웹사이트의 투자자 관계 섹션을 통해 실시간 및 아카이브된 웹캐스트로 접근할 수 있습니다. 이 회사는 혁신적인 의료 기술 솔루션을 통해 심각한 신경학적 상태의 진단 및 관리를 혁신하는 데 집중하고 있습니다.
Ceribell (Nasdaq: CBLL), une entreprise de technologie médicale spécialisée dans le diagnostic neurologique, a annoncé sa participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Jane Chao, Ph.D., PDG et cofondatrice, présentera une intervention le lundi 13 janvier 2025 à 7h30 PST.
La présentation sera accessible via un webinaire en direct et archivé dans la section Relations Investisseurs du site Web de Ceribell. L'entreprise se concentre sur la révolution du diagnostic et de la gestion des conditions neurologiques graves grâce à des solutions technologiques médicales innovantes.
Ceribell (Nasdaq: CBLL), ein medizinisches Technologieunternehmen, das sich auf neurologische Diagnostik spezialisiert hat, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Jane Chao, Ph.D., CEO und Mitgründerin, wird am Montag, den 13. Januar 2025, um 7:30 Uhr PST eine Präsentation halten.
Die Präsentation wird über einen Live- und Archiv-Webcast im Bereich für Investorenbeziehungen auf der Website von Ceribell zugänglich sein. Das Unternehmen konzentriert sich darauf, die Diagnose und Behandlung schwerer neurologischer Erkrankungen durch innovative medizinisch-technologische Lösungen zu revolutionieren.
- None.
- None.
SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 7:30 a.m. Pacific Standard Time.
Event: 43rd Annual J.P. Morgan Healthcare Conference
Date: Monday, January 13, 2025
Time: 7:30 a.m. PST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About Ceribell, Inc.
Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Corrie Rose
Press@ceribell.com
FAQ
When is Ceribell (CBLL) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Ceribell's (CBLL) J.P. Morgan Healthcare Conference presentation?
What is Ceribell's (CBLL) main business focus?
Who will be presenting for Ceribell (CBLL) at the 2025 J.P. Morgan Healthcare Conference?
